Evidence map›Paper›PMID 29137220›Full record

ArticleOncotarget2017

Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth.

Timothy G Pestell, Xuanmao Jiao, Mukesh Kumar, Amy R Peck, Marco Prisco, Shengqiong Deng, Zhiping Li, Adam Ertel, Mathew C Casimiro, Xiaoming Ju and 14 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 9 institutions in 4 countries.

Timothy G PestellDepartments of Cancer Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, PA, USA.
Xuanmao JiaoPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA, USA.
Mukesh KumarDepartments of Cancer Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, PA, USA.
Amy R PeckDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Marco PriscoDepartments of Cancer Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, PA, USA.
Shengqiong DengDepartments of Cancer Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, PA, USA.
Zhiping LiDepartments of Cancer Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, PA, USA.
Adam ErtelDepartments of Cancer Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, PA, USA.
Mathew C CasimiroPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA, USA.
Xiaoming JuDepartments of Cancer Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, PA, USA.
Agnese Di RoccoPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA, USA.
Gabriele Di SantePennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA, USA.
Sanjay KatiyarDepartments of Cancer Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, PA, USA.
Alison ShuppDepartments of Cancer Biology, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, PA, USA.
Michael P LisantiTranslational Medicine, School of Environment and Life Sciences, Biomedical Research Centre, University of Salford, Salford, Greater Manchester, England, UK.
Pooja JainDepartment of Microbiology and Immunology, Institute for Molecular Medicine & Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, USA.
Kongming WuDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hallgeir RuiDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Douglas C HooperDepartment of Microbiology, Thomas Jefferson University, Bluemle Life Sciences Building, Philadelphia, PA, USA.
Zuoren YuPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA, USA.
Aaron R GoldmanMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
David W SpeicherMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
Lisa Laury-KleintopLankenau Institute for Medical Research, Wynnewood, PA, USA.
Richard G PestellPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA, USA.
Thomas Jefferson University · USBaruch S. Blumberg Institute · USMedical College of Wisconsin · USShanghai East Hospital · CNThe Wistar Institute · USHuazhong University of Science and Technology · CNInstitute for Molecular Medicine · USLankenau Institute for Medical Research · USUniversity of Salford · GB

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
Initiation and Maintenance In Mammary TumorigenesisR01CA075503 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 1998 to 2011
$4.6M
Identification of Ovarian Cancer Plasma BiomarkersR01CA131582 · NCI · WISTAR INSTITUTE · PI SPEICHER, DAVID W. · 2009 to 2018
$4.1M
CYCLIN D1 FUNCTION IN PROSTATE CANCERR01CA086072 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 2001 to 2013
$3.3M
REGULATION OF CYCLIN D1 EXPRESSIONR01CA070896 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 2000 to 2010
$3.2M
DACH1/Eya Cell fate determination factor and mammary tumorigenesisR01CA132115 · NCI · THOMAS JEFFERSON UNIVERSITY · PI PESTELL, RICHARD G · 2009 to 2018
$3.1M
Pre-clinical testing of a novel immunotherapy for HTLV-induced neurologic diseaseR01NS097147 · NINDS · DREXEL UNIVERSITY · PI JAIN, POOJA · 2017 to 2021
$2.2M
Prolactin pathways and metastatic progression of ER-positive breast cancerR01CA188575 · NCI · THOMAS JEFFERSON UNIVERSITY · PI RUI, HALLGEIR · 2015 to 2019
$1.8M
Cyclin D1 Regulation of Nuclear Receptor Function in Breast CancerR01CA107382 · NCI · THOMAS JEFFERSON UNIVERSITY · PI PESTELL, RICHARD G · 2004 to 2008
$1.6M
NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA070896NCI NIH HHS R01 CA075503NCI NIH HHS R01 CA086072NCI NIH HHS R01 CA107382NCI NIH HHS R01 CA131582NCI NIH HHS R01 CA132115NCI NIH HHS R01 CA188575NINDS NIH HHS R01 NS097147
6 · The paper itself

Abstract

The

Indexed as

breast cancerCAFscyclin D1OPNstem cell

Identifiers

PMID29137220
PMCPMC5669846
OpenAlexW2743860931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.